Invitation to Presentations of Senzime's First Quarter 2026 Report

Rhea-AI Summary

Senzime (OTCQX:SNZZF) invites investors, analysts and media to presentations of its Q1 2026 report on April 22, 2026. The report will be published at 08:00 CEST, followed by a CEO webcast at 09:00 CEST on Senzime's investor site and a live Q&A at 11:00 CEST hosted by Redeye.

Questions for the Q&A must be emailed by April 22, 10:00 CEST to gustaf.meyer@redeye.se. A recording of the Q&A will be posted later the same day on Redeye's website.

AI-generated analysis. Not financial advice.

UPPSALA, SE / ACCESS Newswire / April 17, 2026 / Senzime (STO:SEZI)(OTCQX:SNZZF) - Senzime invites investors, analysts, and media to presentations of the first quarter report for 2026 on April 22. The report will be published at 08.00 am CEST the same day.

Philip Siberg, CEO of Senzime, will present the Q1 report through a webcast that can be seen from 09.00 am CEST on Senzime's website https://www.senzime.com/investors

A Live Q&A, hosted by Gustaf Meyer, analyst at Redeye, will be aired at 11:00 am CEST via Redeyes platform. A recording of the Q&A will be published later the same day via Redeye's website https://www.redeye.se/company/senzime

Questions for the Q&A interview can be emailed in advance, no later than April 22, 10:00 am CEST, to gustaf.meyer@redeye.se

For further information, please contact:

Philip Siberg, CEO of Senzime AB
Phone: +46 (0) 707 90 67 34, e-mail: philip.siberg@senzime.com

Slavoljub Grujicic, CFO
Phone: +46 (0) 76 306 60 11, e-mail: slavoljub.grujicic@senzime.com

About Senzime

Senzime is a leading medical device company at the forefront of a changing healthcare market, driven by new clinical guidelines and emerging technologies. Established in 1999, Senzime develops and markets precision-based monitoring systems that improve outcomes, reduce costs, and advance perioperative patient safety. The flagship solution is the TetraGraph^® system, proven best-in-class for accurate monitoring of neuromuscular transmission during surgery and used in thousands of operating rooms across the globe. The system helps to secure precise dosing of paralytic drugs and provides enhanced insights to safeguard every patient's journey, from anesthesia to recovery.

Headquartered in Uppsala, Sweden, Senzime is publicly traded on the Nasdaq Stockholm Main Market (SEZI), with cross-trading on the US OTCQX Market (SNZZF), and backed by long-term investors. More information is available at senzime.com.

Attachments

Invitation to presentations of Senzime's first quarter 2026 report

SOURCE: Senzime

View the original press release on ACCESS Newswire

FAQ

When will Senzime (SNZZF) publish its Q1 2026 report and where can I access it?

Senzime will publish the Q1 2026 report on April 22, 2026 at 08:00 CEST. According to Senzime, the report will be available on the company's investor website and linked ahead of the CEO webcast beginning at 09:00 CEST.

What time is the Senzime (SNZZF) CEO webcast for the Q1 2026 report on April 22?

The CEO webcast is scheduled for April 22, 2026 at 09:00 CEST. According to Senzime, Philip Siberg will present the Q1 report via webcast on the company's investor site, with the webcast accessible to investors, analysts, and media.

How can investors join the live Q&A for Senzime (SNZZF) on April 22 and when is it?

The live Q&A will be held April 22, 2026 at 11:00 CEST via Redeye's platform. According to Senzime, Gustaf Meyer of Redeye will host the session and a recording will be posted later on Redeye's website.

What is the deadline to submit questions for Senzime (SNZZF) Q1 2026 Q&A and where to send them?

Questions must be emailed by April 22, 2026 at 10:00 CEST to gustaf.meyer@redeye.se. According to Senzime, submissions received by that deadline will be considered for the live Q&A hosted by Redeye.

Will Senzime (SNZZF) provide a recording of the Q1 2026 presentation and where will it be posted?

Yes. According to Senzime, a recording of the live Q&A will be published the same day on Redeye's website. The CEO webcast may also be available on Senzime's investor site for later viewing.